| Original language | American English |
|---|---|
| State | Published - Aug 6 2022 |
Keynote B36: Open-label study of first-line tumor treating fields (150kHz) plus pembrolizumab for non-small cell lung cancer
Research output: Contribution to conference › Presentation
Research output: Contribution to conference › Presentation
| Original language | American English |
|---|---|
| State | Published - Aug 6 2022 |